Torque teno virus among dialysis and renal-transplant patients

Abstract

Patients who undergo dialysis treatment or a renal transplant have a high risk of blood-borne viral infections, including the Torque teno virus (TTV). This study identified the presence of TTV and its genome groups in blood samples from 118 patients in dialysis and 50 renal-transplant recipients. The research was conducted in a hospital in the city of Maringá, state of Paraná. The viral DNA, obtained from whole blood, was identified by using two nested Polymerase Chain Reactions (PCR). The frequencies of TTV were 17% and 36% in dialysis patients using the methodology proposed by Nishizawa et al . (1997) and Devalle and Niel (2004) , respectively, and 10% and 54% among renal-transplant patients. There was no statistically significant association between the frequency of the pathogen and the variables: gender, time in dialysis, time since transplant, blood transfusions, and the concomitant presence of hepatitis B, for either the dialysis patients or the renal-transplant recipients. Among dialysis patients and renal-transplant recipients, genogroup 5 was predominant (48% and 66% respectively), followed by genogroup 4 (37% and 48%) and genogroup 1 (23% and 25%). Genogroup 2 was present in both groups of patients. Some patients had several genogroups, but 46% of the dialysis patients and 51% of the renal-transplant recipients had only a single genogroup. This study showed a high prevalence of TTV in dialysis patients and renal-transplant recipients.

Prevalence of human anelloviruses in Romanian healthy subjects and patients with common pathologies

“…various surgical procedures) represent potential gateways for anelloviral particles access into the blood stream; whilst there are no studies to support this theory, in our study significantly higher rates of anelloviral DNA (Table 2 ) were found in subjects that underwent these procedures. The incidence of TTV DNA in patients undergoing haemodialysis reported by this study (90.6%), all part of the T2DM group, was higher compared to dialyzed patients from Brazil (17–36%) [ 23 ] and France (54%) [ 24 ]; however the discrepancy can be explained also by the different protocols used for molecular detection of viral DNA. For the patients undergoing haemodialysis (T2DM with chronic renal failure) the significantly higher prevalence of anelloviral DNA can be partially explained by this medical procedure.…”

Seroprevalence of Torque Teno Virus in hemodialysis and renal transplant patients in Australia: A cross‐sectional study

“…This may have been a chance finding, given the small numbers involved; however, it is consistent with a Brazilian study which also found a higher prevalence in transplant compared with dialysis patients. 23 Another potential explanation is that TTV is present in >90% of all people, but it may be at viral loads below the level of detection of our assay (500 copies/mL) and hence not be detectable until after immunosuppression. Finally, the prevalence may be truly higher in transplant patients due to more acquisition, but this appears unlikely; for example, previous blood transfusion (one potential mechanism of acquisition) was reported in a similar proportion of dialysis patients (52%) and transplant patients (60%).…”

Current Views of Torque Teno Virus (TTV) in Liver Diseases

“…Имеется ряд работ, посвященных анализу обнаружения TTV у пациентов, проходящих лечение гемодиализом [22,76,78,81]. Обобщая данные, представленные в этих работах, можно сделать вывод, что частота обнаружения ДНК TTV в крови пациентов, подвергающихся процедуре гемодиализа, статистически выше, чем у доноров крови.…”

“…Ряд работ подтверждает, что частота обнаружения ДНК TTV у пациентов, подвергшихся трансплантации органов, статистически выше, нежели до операции или чем у доноров крови [81][82][83]87]. По данным Y. Kanda и соавт., из 25 реципиентов костного мозга 60 % становились инфицированными TTV через 6-12 недель после трансплантации [93].…”